Christopher Cooper

Form D signer

Christopher Cooper

Co-Chief Executive Officer at Shuttle Pharmaceuticals

Form D signer

Capital raised by Shuttle Pharmaceuticals

$10.0M+$10.0M latest round

1 Form D filing · first filed Apr 2026 · Gaithersburg, MD

CURRENT ROLE: Co-Chief Executive Officer
SECTOR: Biotech
COMPANY FILINGS: 1
TEAM ON FILE: 2
FOUNDED: —
30D INTEREST: —

Career

1 company on file

Shuttle PharmaceuticalsBiotech · Gaithersburg, MDsince Apr 2026

Co-Chief Executive Officer

Signatory on Shuttle Pharmaceuticals's Form D filings · $10.0M raised across 1

Company filings

via EDGAR · Form D for Shuttle Pharmaceuticals1

DateCompanyFormAmountRole on filing

Apr 30, 2026Shuttle PharmaceuticalsForm D+$10.0MCo-Chief Executive Officer

Form DApr 30, 2026 · Shuttle Pharmaceuticals+$10.0Mas Co-Chief Executive Officer

Overview

Last filing Apr 30, 2026

Christopher Cooper is on file as Co-Chief Executive Officer at Shuttle Pharmaceuticals in Gaithersburg, MD. Shuttle Pharmaceuticals has 1 Form D filing on record, $10.0M raised in total. Christopher Cooper appears as a signatory on the company's filings.

Teammates

Shuttle Pharmaceuticals · 1

Ryan TrasoliniExecutive Officer

Products

Shuttle Pharmaceuticals · 1

Ropidoxuridine (IPdR)Oncology drug candidate

An orally administered radiation-sensitizing drug candidate given alongside radiotherapy, currently in a Phase 2 clinical trial in newly diagnosed IDH-wildtype glioblastoma with an unmethylated MGMT promoter.